Experience of anti-IL-1β and anti-IL-18 combined therapy (MAS825) in recurrent and recalcitrant macrophage activation syndrome

Journal Article Corrected proof Experience of anti-IL-1β and anti-IL-18 combined therapy (MAS825) in recurrent and recalcitrant macrophage activation syndrome Get access Şengül Çağlayan, Şengül Çağlayan Department of Pediatric Rheumatology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey https://orcid.org/0000-0003-3014-5692 Search for other works by this author on: Oxford Academic PubMed Google Scholar Kadir Ulu, Kadir Ulu Department of Pediatric Rheumatology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey https://orcid.org/0000-0002-8197-6077 Search for other works by this author on: Oxford Academic PubMed Google Scholar Betül Sözeri Betül Sözeri Department of Pediatric Rheumatology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey Correspondence to: Betül Sözeri, Department of Pediatric Rheumatology, University of Health Sciences, Ümraniye Research and Training Hospital, Elmalıkent District, Adem Yavuz Street, 34764 Umraniye/Istanbul, Turkey. E-mail: drbetulsozeri@gmail.com https://orcid.org/0000-0002-5079-5644 Search for other works by this author on: Oxford Academic PubMed Google Scholar Rheumatology, kead612, https://doi.org/10.1093/rheumatology/kead612 Published: 17 November 2023 Article history Accepted: 02 November 2023 Published: 17 November 2023 Corrected and typeset: 05 December 2023